Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

676 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-10-25

Study Completion Date

2019-07-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study assesses immunogenicity and safety of NBP607-QIV to Agrippal which are indicated for active immunization for the prevention of influenza disease. Total of 675 subjects or above (450 subjects for NBP607-QIV arm and 225 subjects for Agrippal arm) of 6 to 35 months of age are enrolled, and each subject is administered with single or two doses of vaccines depending on previous vaccination history.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus

NCT06385821

Influenza Influenza A Influenza, Human +8 more

COMPLETED PHASE3

Trivalent, Live, Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6-59 Months of Age

NCT00128167

Influenza

COMPLETED PHASE3

Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014

NCT00614614

Infections, Meningococcal

COMPLETED PHASE3

Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV

NCT03614702

Poliomyelitis

COMPLETED PHASE3

Persistence of IPV Immunity

NCT03723837

Poliomyelitis

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multi-national, multi-center, randomized, double blinded, parallel-group study to assess the immunogenicity and safety of NBP607-QIV compared to Agrippal which are indicated for active immunization for the the prevention of influenza disease. Total of 675 subjects or above (450 subjects for NBP607-QIV arm and 225 subjects for Agrippal arm) of 6 to 35 months of age are enrolled. Each subject is administered with single or two doses of vaccines depending on previous vaccination history, and randomly assigned in 2:1 ratio.

Stratified randomization for trial site and age strata is used to achieve the balance of treatment assignment.

Total of three or five visits are scheduled depeding on dosing schedule. For subjects assigned to single-dose vaccination schedule, blood sampling is conducted for immunogenicity assessment before and 4 weeks after single vaccination at Visit 1 and 3 respectively. Safety is monitored 3 days, 4 weeks after vaccination through Visit 2\* and 3 (\* telephone contact). For subjects assigned to two-dose vaccination schedule, blood sampling is conducted before first vaccination and 4 weeks after second vaccination at Visit 1 and Visit 5 respectively. Safety is monitored 3 days, 4 weeks after each vaccination through Visit 2\*, 3, 4\*, and 5 (\* telephone contact)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NBP607-QIV

One or two doses of 0.5mL of NBP607-QIV by intramuscular injection

Group Type EXPERIMENTAL

NBP607-QIV

Intervention Type BIOLOGICAL

Purified inactivated influenza virus surface antigens of four strains (quadrivalent)

Agrippal

One or two doses of 0.25mL of Agrippal by intramuscular injection

Group Type ACTIVE_COMPARATOR

Agrippal

Intervention Type BIOLOGICAL

Influenza virus surface antigens of three strains (trivalent)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NBP607-QIV

Purified inactivated influenza virus surface antigens of four strains (quadrivalent)

Intervention Type BIOLOGICAL

Agrippal

Influenza virus surface antigens of three strains (trivalent)

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children aged 6 to 35 months
* Those who were normal gestational age at birth (for children aged 6 months to \<1 year)
* Those who have provided written informed consent to study participation and compliance with study instructions after being informed of and understand details of the study

Exclusion Criteria

* Those with any immunodeficiency disease or malignancy
* Those with hypersensitivity to vaccination
* Those who are contraindicated for intramuscular injection due to thrombocytopenia or other coagulopathy
* Those with history of treatment with any of immunosuppressants or immunoregulators within 12 weeks prior to screening
* Those with history of receiving blood product or treatment with immunoglobulin within 24 weeks prior to screening
* Those with history of influenza vaccination within 24 weeks prior to screening
* Those with any severe chronic conditions that interfere with study participation

Minimum Eligible Age

6 Months

Maximum Eligible Age

35 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes